Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 14Terminated 6Recruiting 4Active not recruiting 3Not yet recruiting 2Unknown 1

Sponsor Class

OTHER 5INDUSTRY 2OTHER_GOV 1

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2

Conditions

Carcinoma, Non-Small-Cell Lung 76Breast Neoplasms 53Colorectal Neoplasms 51Neoplasms 38Advanced Solid Tumors 34Multiple Myeloma 32Prostatic Neoplasms 31Ovarian Neoplasms 28Neoplasm Metastasis 28Recurrence 27Lung Neoplasms 27Carcinoma, Hepatocellular 27Pancreatic Neoplasms 26Advanced Solid Tumor 22Small Cell Lung Carcinoma 20Leukemia, Myeloid, Acute 20Endometrial Neoplasms 19Melanoma 18Triple Negative Breast Neoplasms 16Squamous Cell Carcinoma of Head and Neck 14Lymphoma, Follicular 14Stomach Neoplasms 13Lymphoma, B-Cell 13Glioma 13Glioblastoma 13Uterine Cervical Neoplasms 12Lymphoma 11Head and Neck Neoplasms 11Solid Tumor 10Myasthenia Gravis 9

Interventions

belantamab mafodotin 1Dexamethasone 1Cyclophosphamide 1Bortezomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Not yet recruiting × INDUSTRY × Immunoglobulin Light-chain Amyloidosis × Clear all
NCT07224672 2026-03-17

ALANIS

GlaxoSmithKline

Phase 2 Not yet recruiting
60 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Amyloidosis

NCT07055724 2025-07-09

Study of Eque-cel CAR-T Therapy in Newly Diagnosed Severe AL Amyloidosis

Nanjing IASO Biotechnology Co., Ltd.

Phase 2 Not yet recruiting
17 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡